Please use this identifier to cite or link to this item:
http://repositorio.ufla.br/jspui/handle/1/41464
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Rojas, Manuel | - |
dc.creator | Rodríguez, Yhojan | - |
dc.creator | Monsalve, Diana M. | - |
dc.creator | Acosta-Ampudia, Yeny | - |
dc.creator | Camacho, Bernardo | - |
dc.creator | Gallo, Juan Esteban | - |
dc.creator | Rojas-Villarraga, Adriana | - |
dc.creator | Ramírez-Santana, Carolina | - |
dc.creator | Díaz-Coronado, Juan C. | - |
dc.creator | Manrique, Rubén | - |
dc.creator | Mantilla, Ruben D. | - |
dc.creator | Shoenfeld, Yehuda | - |
dc.creator | Anaya, Juan-Manuel | - |
dc.date.accessioned | 2020-06-17T19:05:45Z | - |
dc.date.available | 2020-06-17T19:05:45Z | - |
dc.date.issued | 2020-07 | - |
dc.identifier.citation | ROJAS, M. et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmunity Reviews, [S.l.], v. 19, n. 7, July 2020. | pt_BR |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S1568997220301166 | pt_BR |
dc.identifier.uri | http://repositorio.ufla.br/jspui/handle/1/41464 | - |
dc.description.abstract | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality. | pt_BR |
dc.language | en_US | pt_BR |
dc.publisher | Elsevier | pt_BR |
dc.rights | restrictAccess | pt_BR |
dc.source | Autoimmunity Reviews | pt_BR |
dc.subject | Coronavirus | pt_BR |
dc.subject | COVID-19 | pt_BR |
dc.subject | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | pt_BR |
dc.subject | Convalescent plasma | pt_BR |
dc.subject | Cytokines | pt_BR |
dc.subject | Intravenous immunoglobulins | pt_BR |
dc.subject | Neutralizing antibodies | pt_BR |
dc.subject | ACE-2 receptor | pt_BR |
dc.title | Convalescent plasma in Covid-19: possible mechanisms of action | pt_BR |
dc.type | Artigo | pt_BR |
Appears in Collections: | FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19) |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.